Combination therapy as first-line treatment for hypertension

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Systemic hypertension is a major risk factor for atherosclerotic vascular disease and acute events like stroke.
• High-risk patients, including those with diabetes mellitus, require aggressive blood pressure (BP) targets to reduce cardiovascular events.
• Traditional step therapy is insufficient for rapidly achieving low BP targets in high-risk individuals.

Purpose of the Study:

• To advocate for combination therapy in managing hypertension, particularly in high-risk patient populations.
• To highlight the benefits of single-pill combinations for improving patient compliance and therapeutic efficacy.
• To propose an updated treatment approach utilizing effective doses of renin-angiotensin aldosterone system (RAAS) blocker/calcium channel antagonist (CCA) combinations.

Main Methods:

• Review of recent studies comparing different antihypertensive combination therapies.
• Emphasis on the efficacy of RAAS blockers and calcium channel antagonists (CCAs).
• Consideration of patient compliance and the advantages of single-pill formulations.

Main Results:

• Combination therapy with at least two potent medications is more effective than monotherapy for rapid BP reduction.
• Single-pill combinations of RAAS blockers and CCAs are superior to older diuretic-based combinations in preventing cardiovascular events.
• This approach facilitates rapid BP reduction to target levels, such as below 130/80 mmHg.

Conclusions:

• Combination therapy, specifically RAAS blocker/CCA single-pill combinations, is recommended for high-risk hypertensive patients.
• This strategy effectively lowers BP rapidly and to aggressive targets, thereby reducing the risk of vascular events.
• Increased availability and patient preference for combination pills enhance therapeutic adherence and outcomes.